SCHEMBL14745879

SCHEMBL14745879

COC(=O)c1c(O)c2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1cc3cc(CO[Si](C)(C)C(C)(C)C)n(C)c3cc1OCC2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.34
MAPT P10636 7/20 0.32
POLB P06746 2/20 0.32
AADAT Q8N5Z0 1/20 0.32
ALDH1A1 P00352 4/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
NPC1 O15118 1/20 0.31
PKM P14618 1/20 0.31
RAB9A P51151 1/20 0.31
TP53 P04637 1/20 0.31
LMNA P02545 2/20 0.31
KDM4E B2RXH2 1/20 0.31
GHSR Q92847 1/20 0.31
HPGD P15428 1/20 0.30
ALOX5AP P20292 1/20 0.30
ROCK2 O75116 1/20 0.30
EDNRB P24530 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14746202 0.90 EGLN1 (0.35) EGLN1MAPTAADATALDH1A1MEN1
SCHEMBL16429056 0.89 EGLN1 (0.36) EGLN1MAPTPOLBALDH1A1MEN1
SCHEMBL14745781 0.89 EGLN1 (0.35) EGLN1MAPTPOLBAADATALDH1A1
SCHEMBL16429204 0.89 EGLN1 (0.35) EGLN1MAPTPOLBAADATALDH1A1
SCHEMBL14745619 0.89 EGLN1 (0.34) EGLN1MAPTPOLBAADATALDH1A1
SCHEMBL14745913 0.88 EGLN1 (0.34) EGLN1MAPTPOLBAADATALDH1A1
SCHEMBL14746104 0.86 EGLN1 (0.33) EGLN1MAPTAADATALDH1A1NPC1
SCHEMBL14745386 0.86 EGLN1 (0.33) EGLN1MAPTAADATALDH1A1NPC1
SCHEMBL16428781 0.85 P2RX3 (0.37) EGLN1MAPTAADATALDH1A1MEN1
SCHEMBL14745742 0.84 EGLN1 (0.35) EGLN1MAPTALDH1A1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EGLN1 712/4885MAPT 4110/4885POLB 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.